On January 5, 2026 Sanofi K.K. (hereinafter "Sanofi") and Taiho Pharmaceutical Co., Ltd. (hereinafter "Taiho") reported that the sales of the anticancer agent Jevtana I.V. Infusion 60 mg (generic name: cabazitaxel; hereinafter "Jevtana") will be transferred from Sanofi to Taiho in Japan effective April 1, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jevtana is an anticancer agent which was approved and launched in Japan in 2014, indicated for patients with castration-resistant prostate cancer previously treated with a docetaxel-containing regimen. The agent inhibits cell division by promoting tubulin polymerization and stabilizing microtubules, thereby suppressing the proliferation of cancer cells.

On April 1, 2026, Taiho will assume responsibility for the sales and marketing, and medical information activities for Jevtana in Japan, while Sanofi will continue to be the marketing authorization holder and will also continue to manufacture the product.

Sanofi and Taiho remain committed to ensuring a smooth transition and continued supply of Jevtana to patients in need of this treatment.

(Press release, Taiho, JAN 5, 2026, View Source [SID1234661724])